Viking Therapeutics, a clinical-stage biopharma listed on Nasdaq under the ticker VKTX, released its third-quarter 2026 financial statements on October 28. The company posted a net loss of $183.2 million, equating to $1.55 per share, while ending the quarter with a cash and short-term investment balance of $960 million. The loss reflects heavy spending on research, development, and the expansion of multiple Phase 3 programs aimed at treating obesity and related metabolic disorders.
Quarterly financial picture and cash strategy
Research and development outlays surged to $166.8 million for the quarter, up from $90 million in the same period a year earlier, primarily driven by larger clinical-trial budgets and manufacturing costs for candidate drugs. General and administrative expenses more than doubled, reaching $20.3 million versus $8.6 million in 2025, as legal fees and consulting services climbed. Despite the widening loss—totaling $469.5 million over the nine-month period—Viking raised $575 million through concurrent public offerings of common stock and convertible senior notes, bolstering its liquidity runway.
Advances in the VK2735 obesity franchise
The centerpiece of Viking’s pipeline is VK2735, a dual GLP-1/GIP agonist being developed in both subcutaneous and oral formats. In the subcutaneous arm, the ongoing VANQUISH Phase 3 trials continue to enroll rapidly, with 4,500 patients recruited for VANQUISH-1 within five months and an additional 1,000 participants added to VANQUISH-2, which also explores effects on type-2 diabetes. Interim data from the Phase II VENTURE study showed mean weight reductions of up to 14.7 % after 13 weekly injections, with no plateau observed.
The oral formulation entered the SUNRISE Phase 3 program, mirroring the subcutaneous design but delivering the drug via daily tablets. Phase II results demonstrated a mean loss of 12.2 % after 13 daily doses, prompting the launch of two parallel SUNRISE studies targeting 560 adults each, with dosing tiers of 27.5 mg, 35 mg, and 55 mg over 68 weeks. Moreover, a top-line read-out from a maintenance dosing study confirmed that switching from an induction phase to less-frequent regimens—every other week or monthly subcutaneous injections—preserved 82 %-97 % of the initial weight loss at week 33, compared with only 61 % in the placebo arm.
Pipeline diversification and upcoming milestones
Beyond VK2735, Viking is moving forward with a Phase 1 single-ascending-dose (SAD) trial of VK3019, a dual amylin and calcitonin-receptor agonist. The study is approaching completion, and the company plans to launch a 28-day multiple-ascending-dose (MAD) trial in the first quarter of 2027. These efforts broaden Viking’s mechanistic portfolio, positioning it to address metabolic disease from multiple angles.
Management underscored the strategic advantage of offering both a tablet and a subcutaneous injection of the same active molecule. CEO Brian Lian explained that this dual-delivery model could enhance patient adherence and reduce side-effect burden when the same agent is used throughout both induction and long-term maintenance phases. The company also announced the recruitment of senior leaders for technology operations, chemistry-manufacturing-control, and supply-chain functions, laying groundwork for a potential commercial launch of VK2735.
Cash burn is projected at roughly $100 million per quarter, though the CFO warned that certain periods could see higher expenditures as late-stage trials and commercialization preparations intensify. Nevertheless, the strong balance sheet offers flexibility to advance multiple registration programs and to respond to regulatory feedback without immediate financing pressure.
